| Identification | Back Directory | [Name]
[[2,2′-(1,2-Dimethyl-1,2-ethanediylidene)bis[N-methylhydrazinecarbothioamidato]]] copper | [CAS]
68341-09-3 | [Synonyms]
CUAM
Cu-ATSM
Cu-ASTM
CuII(atsm)
Cu-ASTM >=98% (HPLC)
Diacetylbis(N(4)-methylthiosemicarbazonato) copper(II)
[[2,2′-(1,2-Dimethyl-1,2-ethanediylidene)bis[N-methylhydrazinecarbothioamidato]]] copper | [Molecular Formula]
C8H14CuN6S2 | [MDL Number]
MFCD20275141 | [MOL File]
68341-09-3.mol | [Molecular Weight]
321.913 |
| Hazard Information | Back Directory | [Uses]
Cu-ATSM is preclinically used as a potential therapy for ALS (amyotrophic lateral sclerosis). A potential anti-Alzheimer''s agent. | [Biochem/physiol Actions]
Cu-ATSM is an orally bioavailable, blood-brain barrier permeable complex that specifically inhibits the action of peroxynitrite on Cu,Zn superoxide dismutase (SOD1) and subsequent nitration of cellular proteins. CuII(ATSM) significantly delayed onset of disease (paralysis and prolonged lifespan) in amyotrophic lateral sclerosis (ALS) mice model. Also, Cu-ATSM was reported to lower lipid peroxidation in a model of ischemicreperfusion injury. Cu-ATSM subsequently was shown to inhibit ferroptosis with a potency similar to Liproxstatin-1. | [in vivo]
CuATSM (1.5 mg/kg, iv, single dose) reduces cerebral infarct volume and oxidative stress, exhibits neuroprotective effect against ischemic stroke in mouse model[2].
| Animal Model: | Mouse transient middle cerebral artery occlusion (tMCAO) model[2] | | Dosage: | 1.5 mg/kg | | Administration: | iv, single dose | | Result: | Reduced the expression of oxidative stress markers such as 4-HNE, 8-OHdG, and nitrotyrosine. |
| [storage]
Store at -20°C |
|
| Company Name: |
Sigma-Aldrich
|
| Tel: |
021-61415566 800-8193336 |
| Website: |
https://www.sigmaaldrich.cn |
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|